Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGFRL1 | Q5TC84 | 18/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.70 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.70 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16917792 | 1.00 | OGFRL1 (0.70) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL15004422 | 0.99 | OGFRL1 (0.72) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL15004457 | 0.91 | OPRM1 (0.70) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL18240336 | 0.91 | OPRM1 (0.70) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL18240337 | 0.91 | OPRM1 (0.70) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL18240331 | 0.90 | OGFRL1 (0.74) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL18645858 | 0.90 | OGFRL1 (0.74) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL15680038 | 0.90 | OGFRL1 (0.74) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL852958 | 0.89 | OPRM1 (0.70) | OGFRL1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL21547905 | 0.89 | OPRM1 (0.70) | OGFRL1OPRM1OPRK1OPRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290488-B2 | Azetidine-substituted quinoxalines as opioid receptor like-1 modulators | PURDUE PHARMA L.P. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290488-B2 | Azetidine-substituted quinoxalines as opioid receptor like-1 modulators | PURDUE PHARMA L.P. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-01-08 | — | — | US | disclosed |
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QDPR, P2RX5, P2RX1 | OGFRL1 1197/4885OPRM1 19/4885OPRK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.